ESMO 2024

4-year update of Riboclib in EBC - can we avoid chemo?

Hypofractionation in early breast cancer

Therapy de-escalation and balancing individualized therapy management in early breast cancer patients

New updates from the innovative I-SPY program

Escalation, De-escalation and management of therapy: how to identify the best treatment option for our patients?

Survival data from WSG-TP-II

Compliance is everything

Overall survival advantage for Pembrolizumab in early TNBC

Survival benefit reported with Pembro

Registry data from France - no break in endocrine therapy in young patients

Physical exercise and oncological outcome

Endocrine therapy in triple-positive premenopausal patients

4-year landmark data

Evaluation of the patient collective under 40 years

Update on NATALEE in young patients

Ribociclib in younger patients

Physical exercise and oncological outcome

Update on NATALEE in young patients

T-DXD for everyone - what is the minimal threshold for HER2: How to sequence therapies?

De-Escalation in the metastatic setting

Highlights of ESMO 2024

Brain imaging screening in MBC patients

Brain imaging screening in MBC patients

TILs and overall survival in the shortHER trial

Akt-inhibition works with HR+ but not with mTNBC

Keep the patients trained!

New approaches to treat 1L patients mTNBC

No benefit of Akt-inhibition in mTNBC

PIK3CA is not a vaild pathway in triple-negative breast cancer

Nuovi approcci per il trattamento dei pazienti 1L mTNBC

TILs e sopravvivenza nello studio shortHER

Punti salienti di ESMO 2024

PIK3CA is not a vaild pathway in triple-negative breast cancer

New first choice treatment for patients with brain metastases?

Promosing results for the new ADC in HR+ - negative results for pAKT inhibitors in mTNBC: we have to better understand the biology.

Primary systematic treatment of active brain metastases

Optimization treatment with ADCs in endocrine therapy

Primary results of DB-12

Study impression in HR+/HER2- mBC progressing after two lines of therapy

ctDNA data and clinical efficacy of SG

T-Dxd in patients with and without brain metastases

Outstanding efficacy of T-Dxd in CNS meastases

Her3-Dxd - new application area for ADCs

T-Dxd in BrainMets

High sensitivity testing as outcome predictor for T-DXD in mBC

HER3- DXd in the ICARUS Breast-01 study

Efficacy of T-Dxd in patients with brain metastasis

Endocrine-based therapy in combination with dual blockade

Soon no chemotherapy for triplenegative mBC

Optimization treatment with ADCs in endocrine therapy

Risultati primari dello studio DB-12

Impression d'étude dans le cancer du sein métastatique HR+/HER2- progressant après deux lignes de traitement

Impressione dello studio nel carcinoma mammario metastatico HR+/HER2- in progressione dopo due linee di terapia

Endocrine resistance to CDK4/6 inhibitors

Screening for brain metastases – what do doctors and patients think about it?

CTCs as surrogate markers for endocrine therapy

Niraparib in ovarian cancer without survival benefit

The importance of markers for patient management

Overview on the perioperative treatment landscape

BR31: The first negative adjuvant study in resected NSCLC

Perioperative IO Therapy - adjuvant necessary?

Significant CNS protection by osimertinib

ctDNA - a promising new biomarker in early lung cancer

Negative adjuvant CPI trial

Durvalumab did not meet primary endpoint in CCTG BR.31 trial

Should we move away from adjuvant immunotherapy?

Neoadjuvant vs. Perioperative

Getting rid of it will save your life!

BR31: La première étude d’immunothérapie adjuvante négative dans les CBNPC réséqués

Eliminarlo potrebbe salvarti la vita

Durvalumab non ha raggiunto l'endpoint primario nello studio CCTG BR.31

Should we move away from adjuvant immunotherapy?

New 1st line treatment opportunities in advanced stage NSCLC

Update on genetic alterations - ALK / ROS / KRAS / BRAF

Pieces of evidence in the EGFR domain

The next generation of ROS inhibitors

Early mechanisms of resistance from MARIPOSA

4th generation with ALK-alterations

Bispecific antibodies better than ADCs?

Sustained OS at 2nd interim analysis in MARIPOSA-2

NVL-655: a promising new ALK inhibitor

Half of the dose - same activity: provocative findings from NVALT-30

Two sometimes may be better than one!

Optimizing the dose of immunotherapy

Promising signal for anti-TIGIT + anti-PD-1 with PD-L1 > 50 %

Second interim analysis of MARIPOSA-2

Quality of life with Telisotuzumab in LUMINOSITY

NVL-520 for ROS alteration - already best in class?

The next generation of ALK inhibitors

MARIPOSA - lower rate of MET amplification and EGFR resistance mutation

NVALT: 1st attempt to reduce dose of pembrolizumab and limit the financial burden

Patterns of resistance in MARIPOSA trial

1st line encorafenib + binimetinib: combination is very active but PFS very different

Adding anti-LAG-3 doesn't seem to being worth it

RELATIVITY-104: efficacy of anti immunotherapy

Survival Data with Amivantamab for EGFR Alteration

Optimizing the dose of immunotherapy

NVALT: Première tentative pour réduire la dose de pembrolizumab dans les CBNPC de stade IV et réduire le cout du traitement

2 a volte sono meglio di uno

Patterns of resistance in MARIPOSA trial

Quality of life with Telisotuzumab in LUMINOSITY

RELATIVITY-104: efficacy of anti immunotherapy

CBNPC muté BRAF en 1ère ligne : encorafenib + binimetinib : association très active mais la SSP très différente selon les études

Second interim analysis of MARIPOSA-2

Aggiungere l'anti-LAG-3 non sembra valerne la pena

New data on SCLC and mesothelioma

Subset analysis from ADRIATIC

New standard of care in LS-SCLC

Neuer Behandlungsstandard beim LS-SCLC

Response assessment in mesothelioma - can AI help?

Is the radiologist redundant in mesothelioma RECIST measurements

Is the radiologist redundant in mesothelioma RECIST measurements

Doublet therapy in prostate cancer: Practice changing or rather practice informing?

IO in mCRPC: Let's move on to the next substance?!

Practice changing- Big Revival - Or just a Splish? Don't forget the bone protection!

New PSMA-ligand

PSMA-radioligand - the first study of its kind

Radium and enzalutamide in mCRPC - final results

We come in PEACE

Darolutamide in mHSPC

LuPSMA moves UpFront

Not a Patch on ADT?

New hormone therapy for mCRPC

Molecular analysis from PEACE-1

Was it a splash or was it a splish?

Metformin in mHSPC

Did CONTACT make any contact?

Upfronts in personal

Immunotherapy for prostate cancer

Radium223 Prior to Docetaxel Improves Quality of Life in Bone-Dominant mCRPC: Findings from the RAPSON Phase 2 Trial

Radium-223 an option again?

New PSMA-ligand

PSMA-radioligand - the first study of its kind

Radium and enzalutamide in mCRPC - final results

Molecular analysis from PEACE-1

Microbiome transplantation in RCC – how to tailor this therapy for our patients

Where is the right place for HIF inhibitors in advanced RCC therapy?

IO after IO – is there a role for sequential immunotherapy in RCC?

Establishing ICI as standard of care in RCC

SUNNIFORECAST - rain or shine?

mRCC ≥ 1L? News on intensification?

HIF-2a inhibitors are on their way

Treating nccRCC - Nivo/Ipi as a new potential option

FMT in a novel setting

Glycoproteins as Predictive Biomarkers for Nivolumab Plus Cabozantinib Response in Advanced Renal Cell Carcinoma

Ipi-Nivo in nccRCC

The role of sequencing therapy in RCC

Updated survival results

My view on SUNNIFORECAST

TKI monotherapy remains standard in 2ndL

IO therapy is standard for nccRCC

Stool transplantation is the shit

Sequencing checkpoint inhibitors - the story is over

Opening a new way of treatment in MIBC

New SOC for non-cc-RCC?

CPI - modification / prediction - fact or fantasy?

Immunotherapy for nccRCC

Se abre una nueva vía de tratamiento en el cáncer de vejiga con invasión muscular

Sequencing checkpoint inhibitors - the story is over

Tratamiento del nccRCC - Nivo/Ipi como nueva opción potencial

Chemo + IO in the perioperative setting - new standard of care

Encouraging data - but we need more data!

Biomarkers in Bladder cancer - the road to individualized therapy

NIAGARA sets new standard

New data on ADCs in bladder cancer

TAR200 intravesical +/- Cetrelimab in HR (N)MIBC

New standard: perioperative MIBC-NIAGARA

EV + Pembro is broadly effective

Practice changing new data in Bladder cancer at ESMO24

mUC - new ADC's?

Value of ctDNA

Is intravesical therapy as easy as baking a pretzel?

A new way to give chemo for patients who are ineligible for neoadj therapy

Pretzel therapy for superficial UC

Nivolumab Plus Gemcitabine-Cisplatin Maintains Quality of Life in Metastatic Urothelial Carcinoma

Practice changing new data in Bladder cancer at ESMO24

Nuevos datos sobre las ADC en el cáncer de vejiga

A new way to give chemo for patients who are ineligible for neoadj therapy